Dermatologicals in Ireland

PROSPECTS

Topical treatments continue to gain in popularity by directly targeting problem

Topical antifungals and the smaller niche of topical allergy remedies/antihistamines are growing in popularity in Ireland as concerns increase amongst Irish consumers regarding oral medication, particularly amongst those consumers who struggle to swallow large pills. There is also a perception amongst consumers that directly targeting a specific area with a topical treatment may produce faster and more effective results.

Irish parents happy to invest in babies’ comfort with leading nappy rash treatments

Nappy (diaper) rash treatments continued to be a popular form of dermatologicals in Ireland in 2019, recording stable demand amongst parents. An ongoing increase in the average unit price, which is predicted to continue over the forecast period, will not be enough to deter Irish parents from investing in their babies’ comfort, particularly as strong economic growth is now leading to increasing disposable incomes.

Salon treatments offer competition to dermatologicals with alternative treatments

Salon treatments pose increasing competition to some dermatologicals in Ireland, as consumers seek expert advice on how best to address various conditions. With increasing disposable incomes, Irish consumers are investing in treating certain skin conditions with alternative methods where once they would have perceived these to be expensive; light therapy and non-invasive cosmetic surgery are two alternative treatments that are increasing in popularity.

COMPETITIVE LANDSCAPE

McNeil Healthcare retains narrow lead but suffers strong share loss

McNeil Healthcare (Ireland) Ltd retained a narrow lead over its closest competitor Bayer Ltd in 2019. Both are leading players in their respective categories with McNeil Healthcare dominating hair loss treatments with its Regaine line and haemorrhoid treatments with Anusol, while Bayer leads topical antifungals with Canesten and nappy (diaper) rash treatments with Bepanthen.

Zovirax continues to dominate cold sore treatments but McNeil offers alternative product

Zovirax from GSK Consumer Healthcare continued to dominate cold sore treatments, benefiting not only from strong brand loyalty and being synonymous with cold sore treatments but also the increasing popularity of the category in 2019. Consumers who suffer from cold sores want to trust that the treatment they choose to address this issue will work rapidly due to the associated embarrassment and discomfort caused by this virus.

Nizoral experiences change in national brand owner

Medicated shampoo Nizoral, which address dandruff issues, experienced a change in national distribution when new global brand owner STADA Arzneimittel AG moved it from McNeil Healthcare to Clonmel Healthcare Ltd, which also contributed to the negative performance by the former player in 2019. Nizorel was sold by former global brand owner Johnson & Johnson in 2018 to STADA Arzneimittel AG, with the latter attempting to strengthen its overall position within consumer health, and where it is already present in dermatologicals with Hedrin in antiparasitics/lice (head and body) treatments, Polytar in medicated shampoos and Caldease in nappy (diaper) rash treatments amongst others.

Files are delivered directly into your account within a few minutes of purchase.